LARITIN (Artemether and Lumefantrine 20mg/120m) x 12 DISPERSIBLE TABLETS.
Generic Name: Artemether and Lumefantrine
Brand Name: Laritin
Class: Antimalarial combination
Pack Size: 12 tablets
Strength: 20 mg Artemether / 120 mg Lumefantrine per tablet.
Amount: ₦600.

Description: LARITIN combines Artemether and Lumefantrine, offering a powerful artemisinin-based combination therapy (ACT) for the treatment of uncomplicated malaria caused by Plasmodium falciparum. Each tablet contains 20mg of Artemether and 120mg of Lumefantrine. The dispersible tablet formulation is designed to dissolve quickly in water, making it suitable for both adults and children, especially those who may have difficulty swallowing pills.

Key Features:
• Artemisinin-Based Combination Therapy: Utilizes the synergistic effect of Artemether and Lumefantrine for effective malaria treatment.
• Dispersible Tablets: Convenient and easy-to-use formulation, especially for children and patients with swallowing difficulties.
• Rapid Action: Artemether provides a quick reduction in parasite load, while Lumefantrine ensures sustained treatment.
• WHO Approved: Adheres to World Health Organization guidelines for treating uncomplicated malaria.

Side Effects:
Common side effects may include:
• Headache
• Dizziness
• Nausea and vomiting
• Abdominal pain
• Loss of appetite
Less common but serious side effects:
• QT interval prolongation (heart rhythm disorder)
• Hypersensitivity reactions (rash, itching, swelling)
• Severe gastrointestinal symptoms

Caution
• QT Prolongation: Use with caution in patients with a history of QT prolongation or those taking medications known to prolong the QT interval.
• Allergic Reactions: Contraindicated in individuals with known hypersensitivity to Artemether, Lumefantrine, or any other ingredients in the product.
• Drug Interactions: Inform your healthcare provider about all medications and supplements being taken to avoid potential interactions.
• Special Populations: Not recommended for patients with severe malaria, and caution should be exercised in individuals with liver or renal impairment.